TPM3 fusions, although infrequent, have been identified in a wide array of malignancies including colorectal cancer, non‐small cell lung cancer (NSCLC) [7, 8, 9], inflammatory myofibroblastic tumors (IMTs) [10, 11], and thyroid carcinomas [8, 12]. This evidence concerns the gene TPM3 and thyroid gland carcinoma.